Sectors
ASND
Ascendis Pharma A/S
241.34
3 x 240.05
1 x 244.83
bid
ask
-
4.15
1.69%
11:59 AM
timesize
| Ytd | 13.18% | |
| 1y | 53.19% |
239.47
day range
243.59
153.49
52 week range
250.74
| Open | 243.59 | Prev Close | 245.49 | Low | 239.47 | High | 243.59 | Mkt Cap | 14.98B |
| Vol | 149.79K | Avg Vol | 683.98K | EPS | 8.89 | P/E | 27.27 | Forward P/E | 22.23 |
| Beta | 0.48 | Short Ratio | 2.71 | Inst. Own | 106.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-30 | 50-d Avg | 231.78 | 200-d Avg | 213.38 | 1yr Est | 297.14 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-07 | 2026-03 | 0.21 | 0.32 | 0.11 | 52.38% |
| 2026-02-11 | 2025-12 | 0 | N/A | -0.58 | -966.67% |
| 2025-11-12 | 2025-09 | 0 | N/A | -0.76 | -185.37% |
| 2025-08-07 | 2025-06 | 0 | N/A | 0.49 | 34.51% |
| 2025-05-01 | 2025-03 | 0 | N/A | -0.1 | -6.41% |
| 2025-02-12 | 2024-12 | 0 | N/A | 0.52 | 43.33% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-11 | Barclays | Upgrade | Overweight | Overweight |
| 2026-05-08 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2026-04-16 | B of A Securities | Upgrade | Buy | Buy |
| 2026-04-09 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-03-03 | RBC Capital | Upgrade | Outperform | Outperform |
| 2026-02-12 | Oppenheimer | Upgrade | Outperform | Outperform |
Profile
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-10 | JENSEN FLEMMING STEEN | Officer | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | SBI Securities Co., Ltd. | 3.00 | 736.00 | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-04-29 | First Trust Exchange-Traded Fund III-First Trust Long/Short Equity ETF | 15.59K | 3.83M | 0.00% |
| 2026-04-29 | AdvisorShares Trust-AdvisorShares Dorsey Wright ADR ETF | 5.59K | 1.37M | 0.00% |
| 2026-04-29 | Invesco Exchange-Traded Fund Trust II-Invesco Nasdaq Biotechnology ETF | 3.27K | 803.00K | 0.00% |
| 2026-04-29 | First TRT Exch-Trd Fd. II-First TRT IPOX Europe Eqy. Opportunities ETF | 118.00 | 28.97K | 0.00% |
| 2026-04-29 | First TRT Exch-Trd Fd. VIII-First TRT Innovation Leaders ETF | 13.80K | 3.39M | 0.00% |
| 2026-04-29 | Invesco Exch-Trd Fd. TRT II-Invesco RAFI Developed Markets ex-U.S. Sma | 996.00 | 244.51K | 0.00% |
